General form of registration statement for all companies including face-amount certificate companies

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)

v3.22.4
Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 03, 2022
USD ($)
$ / shares
shares
Aug. 01, 2022
USD ($)
$ / shares
shares
May 31, 2022
USD ($)
$ / shares
shares
Feb. 28, 2022
USD ($)
$ / shares
shares
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Aug. 12, 2021
Jul. 31, 2021
Dec. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Common stock, conversion description           minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger   minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.      
Common stock, conversion ratio           1   1      
Working capital         $ 12,323,572 $ 12,323,572   $ 8,526,499      
Accumulated deficit         40,061,534 40,061,534   28,437,993     $ 15,934,113
Cash         14,063,642 14,063,642   10,574,292     663,457
Current liabilities         2,456,293 2,456,293   2,145,996     1,693,744
Revenues           0   0      
Number of common stock sold | shares     11,111 263,729              
Sale of common stock, price per share | $ / shares     $ 9 $ 9              
Gross proceeds from sale of common stock $ 9,100,000   $ 99,999 $ 2,373,561   2,473,560 $ 5,366,170 5,000,000      
Cash equivalents         0 0   0     0
Accumulated deficit         (40,061,534) (40,061,534)   (28,437,993)     $ (15,934,113)
Issuance of common stock $ 9,100,000   $ 99,999 $ 2,373,561   2,473,560 $ 5,366,170 $ 5,000,000      
Proceeds from sale of common stock in initial public offering           $ 11,500,000          
IPO                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of common stock sold | shares   2,000,000                  
Sale of common stock, price per share | $ / shares   $ 5                  
Proceeds from sale of common stock in initial public offering   $ 10,000,000                  
Issuance of common shares         $ 8,750,095            
Overallotment Option                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of common stock sold | shares 300,000                    
Sale of common stock, price per share | $ / shares $ 5                    
Proceeds from sale of common stock in initial public offering $ 1,500,000                    
Offering and Overallotment                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Cash issuance cost, net 2,406,170                    
Issuance of common shares $ 9,093,830                    
DGD or THIO                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of common stock sold | shares             0 0      
MAIA Biotechnology, Inc. | THIO Therapeutics, Inc.                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Ownership percentage by parent                 93.30%    
Minority stockholder ownership percentage                 6.70%    
MAIA Biotechnology, Inc. | MAIA Drug Development Corporation                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Ownership percentage by parent                   100.00%